Filing summary
Entity discrepancy: The request identifies Leonabio, Inc., but the supplied Form 10-Q is for Athira Pharma, Inc. This summary reflects the filing provided. The reporting period ended September 30, 2023; the report was signed November 9, 2023. Financial statements are unaudited.
Business context and reporting period
Athira is a clinical-stage biopharmaceutical company developing small molecules intended to restore neuronal health and slow neurodegeneration. It has no products approved for sale and has generated no product revenue. Its lead candidate, fosgonimeton, is being developed principally for mild-to-moderate Alzheimer’s disease (AD).
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $27.2m | $17.0m | $70.1m | $46.2m |
| General and administrative expense | $7.8m | $7.2m | $26.3m | $24.9m |
| Total operating expenses | $35.0m | $24.1m | $96.5m | $71.1m |
| Net loss | $33.0m | $20.2m | $90.4m | $65.5m |
| Net loss per share | $0.87 | $0.53 | $2.38 | $1.74 |
| Net cash used in operating activities | Not separately stated | Not separately stated | $74.5m | $56.8m |
As of September 30, 2023, cash and cash equivalents were $110.3m and short-term investments were $62.6m; total cash, cash equivalents and investments were approximately $172.9m. There were no long-term investments at quarter-end. Total assets were $184.7m, total liabilities $29.9m, and stockholders’ equity $154.8m. The filing reports operating lease liabilities of $1.7m; it does not report borrowings or other debt financing outstanding.
No operating margin is meaningful given the absence of revenue. Other income, primarily investment interest and discount accretion, was $2.1m for Q3 and $5.9m for the nine-month period. Grant income was nil in Q3 and $0.2m for the nine months; the company says it has recognized the full $15.2m approved NIH grant and will receive no further grant income under it.
Material changes versus prior periods
- Q3 net loss increased $12.8m, or 63%, year over year; nine-month net loss increased $24.9m, or 38%.
- R&D expense rose 60% in Q3 and 52% for the nine months. The principal driver was fosgonimeton clinical-trial activity and manufacturing development; higher staffing costs also contributed.
- G&A increased 9% in Q3 and 6% for the nine months. Nine-month legal costs were lower than the prior-year period, partly offsetting higher personnel and professional-services costs.
- Operating cash use rose to $74.5m from $56.8m for the nine months. Cash, cash equivalents and restricted cash increased $14.6m, largely reflecting investment maturities and purchases rather than operating cash generation.
- Grant income declined substantially compared with 2022 as the approved NIH grant was exhausted. Higher investment income partially offset the greater operating loss.
Outlook, clinical development and key risks
- Management estimates that quarter-end cash, cash equivalents and investments will fund operating expenses and capital expenditures for at least 12 months following the report date. It also says substantial additional funding will be needed; no profitability or positive operating cash flow is assured.
- The company expects enrollment in the amended LIFT-AD Phase 2/3 trial to be completed by Q1 2024 and topline results in the second half of 2024. The trial focuses on 40 mg fosgonimeton in participants not taking background acetylcholinesterase inhibitors (AChEIs); enrollment in the 70 mg arm was discontinued. These are forward-looking estimates, not guaranteed outcomes.
- ACT-AD did not meet its primary or secondary endpoints under the planned analyses. Post hoc findings in a pre-specified subgroup not taking AChEIs were suggestive but not statistically significant and do not establish efficacy. An independent monitoring committee recommended continuing LIFT-AD after an interim analysis, but trial success remains uncertain.
- Following a July 2023 end-of-Phase 2 meeting, the FDA discussed the ongoing trial, dose, AChEI use, biomarkers and statistical plan. The filing says the FDA emphasized demonstrating effects on both cognition and function; it does not report FDA agreement that the trial will support approval.
- A proposed $10m securities-class-action settlement remains subject to court approval. On September 27, 2023, the court denied preliminary approval without prejudice over concerns about traceability of certain claims; plaintiffs were allowed to renew their motion. The $10m liability was accrued in 2022.
- The company is cooperating with a Department of Justice Civil Investigative Demand concerning its relationship with Washington State University (WSU), certain NIH grant applications and a 2020 grant, and with an SEC subpoena concerning, among other things, image alterations by its former CEO.
- A board special committee found that the former CEO altered images in her doctoral dissertation and at least four co-authored research papers; it also found challenged papers had been cited in company communications and applications and that a WSU-licensed dihexa patent incorporated certain altered images. WSU’s review remained ongoing, and its outcome was unknown. The filing warns of potential implications for reputation, licensed intellectual property, grants and investigations.
- Other material risks include clinical-trial delays or failure, patient enrollment, dependence on third-party manufacturers and research providers, additional capital needs and possible shareholder dilution, competition and reimbursement uncertainty, and intellectual-property challenges. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Athira Pharma, not Leonabio.
- Track LIFT-AD enrollment, the 40 mg/no-AChEI trial design, and the timing and full results expected in 2024.
- Review the court’s subsequent handling of the proposed $10m settlement and the status and potential financial impact of derivative litigation and government investigations.
- Assess cash burn against the stated runway, future trial and manufacturing costs, and whether the company uses its $75m at-the-market offering; no shares had been sold under it as of the filing.
- Monitor WSU’s research-misconduct review and any effects on the company’s licensed dihexa-related intellectual property, grants or development programs.